Privacy & Data Security

The administration has signaled a potential softening of cyber regulation for domestic entities, with increasing focus on national security priorities and preparing for the future.

By Antony (Tony) Kim and Michael H. Rubin

The Trump administration’s focus on reshaping the cyber regulatory environment continues with executive order 14306, “Sustaining Select Efforts to Strengthen the Nation’s

@media screen and (max-width: 1023px){section[data-id=”block_e372bcd7803c470c4c97b47880da627a”]{ }}@media screen and (min-width: 1024px) and (max-width: 1365px){section[data-id=”block_e372bcd7803c470c4c97b47880da627a”]{ }}@media screen and (min-width: 1366px){section[data-id=”block_e372bcd7803c470c4c97b47880da627a”]{ }}

As the Covington team discussed in a recent article, use of AI models in biopharma is on the rise, with use cases spanning the life cycle of drugs and biologics, including product development, manufacturing, and pharmacovigilance. Recently, FDA announced its own intentions to aggressively scale the use of AI in regulatory review and launched